Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab
The therapeutic potential of anticancer antibodies is limited by the resistance of tumor cells to complement-mediated attack, primarily through the over-expression of membrane complement regulatory proteins (mCRPs: CD46, CD55 and CD59). Trastuzumab, an anti- HER2 monoclonal antibody, approved for th...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
20 February 2013
|
| In: |
Molecular oncology
Year: 2013, Jahrgang: 7, Heft: 3, Pages: 580-594 |
| ISSN: | 1878-0261 |
| DOI: | 10.1016/j.molonc.2013.02.011 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.molonc.2013.02.011 Verlag, lizenzpflichtig, Volltext: https://febs.onlinelibrary.wiley.com/doi/abs/10.1016/j.molonc.2013.02.011 
|
| Verfasserangaben: | Srinivas Mamidi, Marc Cinci, Max Hasmann, Volker Fehring, Michael Kirschfink |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1760776033 | ||
| 003 | DE-627 | ||
| 005 | 20220819233522.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210617s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.molonc.2013.02.011 |2 doi | |
| 035 | |a (DE-627)1760776033 | ||
| 035 | |a (DE-599)KXP1760776033 | ||
| 035 | |a (OCoLC)1341416629 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mamidi, Srinivas |d 1979- |e VerfasserIn |0 (DE-588)140989471 |0 (DE-627)703851179 |0 (DE-576)321299485 |4 aut | |
| 245 | 1 | 0 | |a Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab |c Srinivas Mamidi, Marc Cinci, Max Hasmann, Volker Fehring, Michael Kirschfink |
| 264 | 1 | |c 20 February 2013 | |
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 17.06.2021 | ||
| 520 | |a The therapeutic potential of anticancer antibodies is limited by the resistance of tumor cells to complement-mediated attack, primarily through the over-expression of membrane complement regulatory proteins (mCRPs: CD46, CD55 and CD59). Trastuzumab, an anti- HER2 monoclonal antibody, approved for the treatment of HER2-positive breast and gastric cancers, exerts only minor complement-mediated cytotoxicity (CDC). Pertuzumab is a novel anti-HER2 monoclonal antibody, which blocks HER2 dimerization with other ligand-activated HER family members. Here, we explored the complement-mediated anti-tumor effects of trastuzumab and pertuzumab on HER2-positive tumor cells of various histological origins. Delivery of chemically stabilized anti-mCRP siRNAs using cationic lipoplexes, AtuPLEXes, to HER2-over-expressing BT474, SK-BR-3 (breast), SKOV3 (ovarian) and Calu-3 (lung) cancer cells reduced mCRPs expression by 85-95%. Knockdown of individual complement regulators variably led to increased CDC only upon combined treatment with trastuzumab and pertuzumab. The combined down-regulation of all the three regulators augmented CDC by 48% in BT474, 46% in SK-BR-3 cells, 78% in SKOV3 cells and by 30% in Calu-3 cells and also increased complement-induced apoptosis and caspase activity on mCRP neutralized tumor cells. In addition, antibody-induced C3 opsonization of tumor cells was significantly enhanced after mCRP silencing and further augmented tumor cell killing by macrophages. Our findings suggest that siRNA-induced inhibition of complement regulator expression clearly enhances complement- and macrophage-mediated anti-tumor activity of trastuzumab and pertuzumab on HER2-positive tumor cells. Thus - if selectively targeted to the tumor - siRNA-induced inhibition of complement regulation may serve as an innovative strategy to potentiate the efficacy of antibody-based immunotherapy. | ||
| 650 | 4 | |a Complement regulatory proteins | |
| 650 | 4 | |a Complement resistance | |
| 650 | 4 | |a Lipoplex | |
| 650 | 4 | |a Pertuzumab | |
| 650 | 4 | |a siRNA | |
| 650 | 4 | |a Trastuzumab | |
| 700 | 1 | |a Cinci, Marc L. |d 1986- |e VerfasserIn |0 (DE-588)1070477397 |0 (DE-627)823904636 |0 (DE-576)430064837 |4 aut | |
| 700 | 1 | |a Hasmann, Max |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fehring, Volker |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kirschfink, Michael |e VerfasserIn |0 (DE-588)120927152 |0 (DE-627)080974457 |0 (DE-576)292452411 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular oncology |d Hoboken, NJ : John Wiley & Sons, Inc., 2007 |g 7(2013), 3 vom: Juni, Seite 580-594 |h Online-Ressource |w (DE-627)531199800 |w (DE-600)2322586-5 |w (DE-576)271586621 |x 1878-0261 |7 nnas |a Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab |
| 773 | 1 | 8 | |g volume:7 |g year:2013 |g number:3 |g month:06 |g pages:580-594 |g extent:15 |a Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.molonc.2013.02.011 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://febs.onlinelibrary.wiley.com/doi/abs/10.1016/j.molonc.2013.02.011 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210617 | ||
| 993 | |a Article | ||
| 994 | |a 2013 | ||
| 998 | |g 120927152 |a Kirschfink, Michael |m 120927152:Kirschfink, Michael |d 910000 |d 911600 |d 50000 |e 910000PK120927152 |e 911600PK120927152 |e 50000PK120927152 |k 0/910000/ |k 1/910000/911600/ |k 0/50000/ |p 5 |y j | ||
| 998 | |g 1070477397 |a Cinci, Marc L. |m 1070477397:Cinci, Marc L. |d 50000 |e 50000PC1070477397 |k 0/50000/ |p 2 | ||
| 998 | |g 140989471 |a Mamidi, Srinivas |m 140989471:Mamidi, Srinivas |d 910000 |d 911600 |e 910000PM140989471 |e 911600PM140989471 |k 0/910000/ |k 1/910000/911600/ |p 1 |x j | ||
| 999 | |a KXP-PPN1760776033 |e 3939120073 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"pubHistory":["1.2007 -"],"language":["eng"],"note":["Gesehen am 25.06.20"],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title":"Molecular oncology","title_sort":"Molecular oncology"}],"disp":"Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumabMolecular oncology","recId":"531199800","name":{"displayForm":["Federation of European Biochemical Societies"]},"part":{"extent":"15","text":"7(2013), 3 vom: Juni, Seite 580-594","volume":"7","pages":"580-594","year":"2013","issue":"3"},"origin":[{"dateIssuedDisp":"2007-","publisher":"John Wiley & Sons, Inc. ; Elsevier","dateIssuedKey":"2007","publisherPlace":"Hoboken, NJ ; Amsterdam [u.a.]"}],"id":{"eki":["531199800"],"zdb":["2322586-5"],"issn":["1878-0261"]}}],"note":["Gesehen am 17.06.2021"],"name":{"displayForm":["Srinivas Mamidi, Marc Cinci, Max Hasmann, Volker Fehring, Michael Kirschfink"]},"recId":"1760776033","id":{"eki":["1760776033"],"doi":["10.1016/j.molonc.2013.02.011"]},"origin":[{"dateIssuedKey":"2013","dateIssuedDisp":"20 February 2013"}],"language":["eng"],"physDesc":[{"extent":"15 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"family":"Mamidi","given":"Srinivas","role":"aut","display":"Mamidi, Srinivas"},{"family":"Cinci","given":"Marc L.","role":"aut","display":"Cinci, Marc L."},{"family":"Hasmann","given":"Max","role":"aut","display":"Hasmann, Max"},{"family":"Fehring","given":"Volker","role":"aut","display":"Fehring, Volker"},{"given":"Michael","role":"aut","family":"Kirschfink","display":"Kirschfink, Michael"}],"title":[{"title":"Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab","title_sort":"Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab"}]} | ||
| SRT | |a MAMIDISRINLIPOPLEXME2020 | ||